Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC12A5 | Q9H2X9 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634342 | 0.80 | NOS1 (0.38) | NOS1SMN1; SMN2SLC12A5CYP2D6KDM4E | |
| SCHEMBL13634285 | 0.80 | MEN1 (0.36) | LMNAKMT2A | |
| SCHEMBL3506347 | 0.79 | MAPK1 (0.42) | NOS1SMN1; SMN2SLC12A5CYP2D6KDM4E | |
| SCHEMBL13999554 | 0.78 | HTR2B (0.35) | ALDH1A1 | |
| SCHEMBL18674691 | 0.76 | ALDH1A1 (0.35) | NOS1SMN1; SMN2SLC12A5CYP2D6KDM4E | |
| SCHEMBL13634391 | 0.76 | NOS1 (0.34) | NOS1SMN1; SMN2SLC12A5CYP2D6KDM4E | |
| SCHEMBL232983 | 0.76 | SMN1; SMN2 (0.40) | NOS1SMN1; SMN2SLC12A5CYP2D6KDM4E | |
| SCHEMBL11321680 | 0.74 | SLC12A5 (0.34) | SMN1; SMN2SLC12A5CYP2D6KDM4ELMNA | |
| SCHEMBL13425206 | 0.73 | KDM4E (0.40) | SMN1; SMN2SLC12A5CYP2D6KDM4ELMNA | |
| SCHEMBL13162306 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | NOS1 1900/4885SMN1; SMN2 3601/4885SLC12A5 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.